MedTrace Logo

Surgicel® Fibrillar for Delayed Bleeding After ESD

NCT01758965 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2014-05-13

No results posted yet for this study

Summary

The aim of this study is to assess the effect of Surgicel® Fibrillar as adjuvant treatment to H2RA on preventing ulcer bleeding after ESD for gastric epithelial tumors

Conditions

  • Benign Neoplasm of Stomach
  • Malignant Neoplasm of Stomach

Interventions

OTHER

PPI

monotherapy of PPI

OTHER

H2RA and surgicel

combination therapy of H2RA and surgicel

Sponsors & Collaborators

  • Soonchunhyang University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01758965 on ClinicalTrials.gov